Last updated: 3 July 2019 at 12:20am EST

John Desjarlais Net Worth




The estimated Net Worth of John S Iii Ronin Capital, L... is at least $137 Million dollars as of 6 June 2019. John L owns over 12,641 units of Xencor Inc stock worth over $107,551,700 and over the last 12 years he sold XNCR stock worth over $27,939,068. In addition, he makes $1,892,510 as Senior Vice President and Research and Chief Scientific Officer at Xencor Inc.

John Desjarlais XNCR stock SEC Form 4 insiders trading

John has made over 27 trades of the Xencor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 12,641 units of XNCR stock worth $377,587 on 6 June 2019.

The largest trade he's ever made was selling 286,671 units of Xencor Inc stock on 1 November 2016 worth over $1,499,289. On average, John trades about 61,412 units every 95 days since 2012. As of 6 June 2019 he still owns at least 5,090,000 units of Xencor Inc stock.

You can see the complete history of John L stock trades at the bottom of the page.





John Desjarlais biography

Dr. John R. Desjarlais Ph.D. serves as Senior Vice President, Research and Chief Scientific Officer of the Company. Dr. Desjarlais has served as our Chief Scientific Officer since July 2014 and served as our Vice President, Research from October 2006 to July 2014. In March 2016, Dr. Desjarlais was appointed Senior Vice President, Research and Chief Scientific Officer. He joined the Company in July 2001, initially serving as our Director of Protein Engineering. Dr. Desjarlais oversees all aspects of discovery and research for the Company, including technology development, protein and antibody engineering and generation of product candidates. Prior to joining us, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University from 1997 to 2001. Dr. Desjarlais received a B.S. in physics from the University of Massachusetts and holds a Ph.D. in biophysics from Johns Hopkins University. He then conducted postdoctoral research at the University of California, Berkeley. Dr. Desjarlais has driven the Company's technology development and engineering efforts for over ten years and participated in the development of the Company's business and intellectual property strategies.

What is the salary of John Desjarlais?

As the Senior Vice President and Research and Chief Scientific Officer of Xencor Inc, the total compensation of John Desjarlais at Xencor Inc is $1,892,510. There are 3 executives at Xencor Inc getting paid more, with Bassil Dahiyat having the highest compensation of $3,731,510.



How old is John Desjarlais?

John Desjarlais is 55, he's been the Senior Vice President and Research and Chief Scientific Officer of Xencor Inc since 2016. There are 9 older and 9 younger executives at Xencor Inc. The oldest executive at Xencor Inc is Richard Ranieri, 67, who is the Independent Director.

What's John Desjarlais's mailing address?

John's mailing address filed with the SEC is 350 N. ORLEANS STREET, SUITE 2N350 N. ORLEANS STREET, SUITE 2N, , CHICAGOCHICAGO, ILIL, 6065460654.

Insiders trading at Xencor Inc

Over the last 11 years, insiders at Xencor Inc have traded over $93,804,287 worth of Xencor Inc stock and bought 1,139,502 units worth $15,515,932 . The most active insiders traders include Capital, Llcstafford John S..., John S Iii Stafford, and John S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of $779,296. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth $536,500.



What does Xencor Inc do?

antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product



What does Xencor Inc's logo look like?

Xencor Inc logo

Complete history of John L stock trades at Aware and Xencor Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
6 Jun 2019 John S Iii Ronin Capital, L...
Buy 12,641 $29.87 $377,587
6 Jun 2019
5,090,000
2 May 2019 John S Iii Ronin Capital, L...
Buy 14,611 $29.87 $436,431
2 May 2019
5,077,359
22 Mar 2019 John S Iii Ronin Capital, L...
Buy 5,500 $29.84 $164,120
22 Mar 2019
5,062,748
15 Mar 2019 John S Iii Ronin Capital, L...
Buy 39,400 $29.04 $1,144,176
15 Mar 2019
5,057,248
14 Sep 2018 John S Iii Ronin Capital, L...
Sale 1,000 $48.05 $48,050
14 Sep 2018
5,017,848
13 Jul 2018 John S Iii Ronin Capital, L...
Sale 111,700 $41.42 $4,626,614
13 Jul 2018
5,018,848
27 Jun 2018 John S Iii Ronin Capital, L...
Sale 138,300 $39.69 $5,489,127
27 Jun 2018
5,130,548
18 Jun 2018 John S Iii Ronin Capital, L...
Sale 250,000 $39.90 $9,975,000
18 Jun 2018
5,261,348
12 Dec 2017 John S Iii Ronin Capital, L...
Buy 9,215 $20.76 $191,303
12 Dec 2017
5,511,348
24 Nov 2017 John S Iii Ronin Capital, L...
Buy 15,374 $19.86 $305,328
24 Nov 2017
5,502,133
8 Nov 2017 John S Iii Ronin Capital, L...
Buy 41,823 $19.91 $832,696
8 Nov 2017
5,485,183
3 Nov 2017 John S Iii Ronin Capital, L...
Buy 27,809 $19.85 $552,009
3 Nov 2017
5,443,360
31 Oct 2017 John S Iii Ronin Capital, L...
Buy 50,000 $19.58 $979,000
31 Oct 2017
5,415,551
25 Oct 2017 John S Iii Ronin Capital, L...
Buy 150,000 $19.81 $2,971,500
25 Oct 2017
5,365,551
21 Aug 2017 John S Iii Ronin Capital, L...
Buy 41,016 $19.69 $807,605
21 Aug 2017
5,215,551
16 Aug 2017 John S Iii Ronin Capital, L...
Buy 147,535 $20.39 $3,008,239
16 Aug 2017
5,174,535
10 Aug 2017 John S Iii Ronin Capital, L...
Buy 27,000 $21.13 $570,510
10 Aug 2017
5,027,000
28 Jun 2017 John S Iii Ronin Capital, L...
Buy 6,000 $19.94 $119,640
28 Jun 2017
5,000,000
16 Jun 2017 John S Iii Ronin Capital, L...
Buy 1,500 $19.67 $29,505
16 Jun 2017
4,994,000
6 Dec 2016 John S Iii Ronin Capital, L...
Sale 63,061 $27.71 $1,747,420
6 Dec 2016
4,992,500
23 Sep 2016 John S Iii Ronin Capital, L...
Sale 40,000 $25.72 $1,028,800
23 Sep 2016
5,055,561
26 Aug 2016 John S Iii Ronin Capital, L...
Sale 24,351 $21.48 $523,059
26 Aug 2016
5,095,561
22 Aug 2016 John S Iii Ronin Capital, L...
Sale 96,828 $21.73 $2,104,072
22 Aug 2016
5,119,912
15 Aug 2016 John S Iii Ronin Capital, L...
Sale 10,000 $23.06 $230,600
15 Aug 2016
5,216,740
9 Aug 2016 John S Iii Ronin Capital, L...
Sale 30,500 $21.87 $667,035
9 Aug 2016
5,226,740
1 Nov 2016 John S Iii Ronin Capital, L...
Sale 286,671 $5.23 $1,499,289
1 Nov 2016
0
21 May 2012 John S Iii Ronin Capital, L...
Buy 16,300 $5.40 $88,020
21 May 2012
2,120,598


Xencor Inc executives and stock owners

Xencor Inc executives and other stock owners filed with the SEC include: